User programme promises to cut review times by a quarter
This article was originally published in Clinica
Executive Summary
The FDA is promising an average 25% improvement in review times with the additional funds collected under the user fee programme. The 25% improvement is an average for all types of premarket submissions, including PMAs, PMA supplements, 510(k)s, and biological licence applications (BLA) used for review of new blood centre devices.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.